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Abstract
 
Cyclosporin A (CsA) is an immunosuppressive drug that inhibits the activity of transcription fac-
tors of the nuclear factor of activated T cells (NFAT) family, interfering with the induction of cy-
tokines and other inducible genes required for the immune response. Here we show that CsA in-
hibits migration of primary endothelial cells and angiogenesis induced by vascular endothelial
growth factor (VEGF); this effect appears to be mediated through the inhibition of cyclooxygen-
ase (Cox)-2, the transcription of which is activated by VEGF in primary endothelial cells. Con-
sistent with this, we show that the induction of Cox-2 gene expression by VEGF requires NFAT
 
activation. Most important, the CsA-mediated inhibition of angiogenesis both in vitro
 
 
 
and
 
 
 
in
 
vivo was comparable to the Cox-2 inhibitor NS-398, and reversed by prostaglandin E
 
2
 
. Further-
more, the in vivo corneal angiogenesis induced by VEGF, but not by basic fibroblast growth fac-
tor, was selectively inhibited in mice treated with CsA systemically. These findings involve
NFAT in the regulation of Cox-2 in endothelial cells, point to a role for this transcription factor
in angiogenesis, and may provide a novel mechanism underlying the beneficial effects of CsA in
angiogenesis-related diseases such as rheumatoid arthritis and psoriasis.
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Introduction
 
Angiogenesis, the formation of new blood vessels from pre-
existing vascular beds, occurs normally during organ devel-
opment and differentiation in embryogenesis, and is re-
quired for wound healing and reproductive functions in the
adult. Angiogenesis is also involved in the pathogenesis of
several disorders including chronic inflammatory diseases
 
and cancer. Vascular endothelial growth factor (VEGF)
 
1
 
 is a
potent endothelial cell mitogen and exerts a pivotal role in
angiogenesis under physiological and pathological condi-
tions (1, 2). Thus, VEGF is crucial for embryonic develop-
ment, as targeted inactivation of even a single VEGF allele
results in embryonic lethality (3), and it is required for sur-
vival in early postnatal life when the endothelium is still
proliferating (4). On the other hand, enhanced expression
of VEGF has been detected in physiological processes asso-
ciated with the menstrual cycle, pregnancy, wound healing,
and pathological conditions including rheumatoid arthritis,
psoriasis, diabetic retinopathy, and cardiovascular and cere-
bral ischemia (5, 6). In addition, a large body of evidence
supports a key role for VEGF in tumorigenesis related to
the requirement of neovascularization for the delivery of
nutrients and oxygen to tumor cells. In fact, VEGF expres-
sion is induced under hypoxic conditions and contributes
to the tumor neovascularization and dissemination (2, 7, 8).
Accordingly, VEGF expression has been found to be in-
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Abbreviations used in this paper:
 
 AA, arachidonic acid; bFGF, basic fibro-
blast growth factor; Cox, cyclooxygenase; CRE, cAMP response element;
CsA, cyclosporin A; EMSA, electrophoretic mobility shift assay; HUVEC,
human umbilical vein endothelial cell; NFAT, nuclear factor of activated T
cells; NSAID, nonsteroidal antiinflammatory drug; PG, prostaglandin; PA,
plasminogen activator; VEGF, vascular endothelial growth factor. 
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creased in nearly every type of cancer analyzed, and anti-
VEGF neutralizing antibodies inhibit tumor growth in vivo
(9–11).
VEGF belongs to a family that also includes the placenta
growth factor (PGF), VEGF-B, VEGF-C, and VEGF-D,
each of which interacts with a different tyrosine kinase re-
ceptor (12, 13). Signaling through these receptors results in
the activation of
 
 
 
phospholipase C
 
g
 
, leading to an increase
in intracellular levels of inositol phosphate and calcium (14,
15). As in other cell types, calcium induces the activation of
calcineurin and nuclear factor of activated T cells (NFAT)
in endothelial cells, a signaling pathway that is blocked by
cyclosporin A (CsA) (16, 17). NFAT is a family of tran-
scription factors (18) that is composed of at least four struc-
turally related members that are expressed in the cytoplasm
of resting cells: NFATc, NFATp, NFAT3, and NFAT4,
also termed NFAT2/NFATc1, NFAT1/NFATc2, NFATc4,
and NFATc3, respectively (19–24), as well as the constitu-
tively nuclear NFAT5/TonE-BP (25, 26). We have re-
cently shown that in human umbilical vein endothelial cells
(HUVECs), VEGF triggers dephosphorylation, transloca-
tion, and activation of NFAT, processes involved in the
regulation of tissue factor gene expression by VEGF (16).
In addition, VEGF has been shown to induce other genes
involved in the degradation of matrix proteins, endothelial
cell migration, and vascular sprouting. Among these genes
are the plasminogen activators (PAs) uPA and PA, the
urokinase receptor (uPAR), and metalloproteinase intersti-
tial collagenase (1, 2, 5).
Cyclooxygenases have been recently implicated in the
regulation of angiogenesis, and Cox inhibition by nonste-
roidal antiinflammatory drugs (NSAIDS) has been shown
to interfere with the production of angiogenic factors (27),
and to inhibit PG synthesis and angiogenesis in colon-26
cells and endothelial cells, respectively (28, 29). Coxs, also
known as prostaglandin endoperoxide synthases, catalyze
the conversion of arachidonic acid (AA) to PGH
 
2
 
, the first
step in the biosynthesis of PGs, thromboxane and prostacy-
clin (30). The two known Cox isoforms differ in their pat-
tern of expression and biology: Cox-1 is constitutively ex-
pressed in most tissues, whereas Cox-2 is inducible in many
cell types in response to a wide variety of stimuli including
antigens, mitogens, hormones, and inflammatory mediators
(31–35). The human Cox-2 gene promoter contains multi-
ple cis-acting regulatory elements including a TATA box,
an E box, and binding sites for important transcription fac-
tors, including a cAMP response element (CRE), NF-IL6
(C/EBP), and NF-
 
k
 
B (36–39). In endothelial cells, Cox-2
is induced in response to multiple stimuli such as TNF-
 
a
 
(40), phorbol esters (41, 42), hypoxia (43), basic fibroblast
growth factor (bFGF; reference 44), IL-1
 
a
 
 (45), and li-
popolysaccharide (36).
To provide new insights into the molecular mechanisms
by which VEGF exerts its angiogenic activity, we have
searched for novel genes regulated by this molecule in HU-
VECs and found that Cox-2 is induced by VEGF. A de-
tailed study of the Cox-2 gene promoter also revealed an
essential role for NFAT in the induction of this gene by
 
VEGF. Because of the ability of CsA to inhibit NFATs and
the role of Cox-2 in angiogenesis, we have tested the effect
of CsA on Cox-2 gene expression and angiogenesis, and
found that CsA blocks both the activation of Cox-2 and
angiogenic effects induced by VEGF. These results may
contribute to a better understanding of the mechanisms un-
derlying the antiangiogenic actions of NSAIDS, and may
also provide explanations for the beneficial effects of CsA
in diseases where pathological neovascularization is associ-
ated with an enhanced expression of VEGF.
 
Materials and Methods
 
Cell Culture and Reagents. 
 
HUVECs were isolated from um-
bilical veins as described previously (46). Cells were serially pas-
saged and cultured using 199 medium (Biowhittaker) supple-
mented with 20% FCS, bovine brain extract, and heparin in
tissue culture flasks precoated with gelatin. Cells were used be-
tween passages 6 and 10. The recombinant human VEGF
 
165
 
 was
purchased from PeproTech. CsA was from Sandoz and Sigma-
Aldrich, and TNF-
 
a
 
 (3.2 
 
3
 
 10
 
7
 
 U/mg) was from Wichem.
 
Western Blot Analysis. 
 
Confluent HUVEC cultures grown in
35-mm tissue culture dishes were maintained before treatment for
12 h in OPTI-MEM (Life Technologies), supplemented with
0.5% FCS. After the different treatments, cells were washed with
cold PBS and lysed in 80 
 
m
 
l Laemmli buffer. Cells extracts were
boiled, separated by SDS-PAGE, and transferred onto nitrocellu-
lose membranes that were then incubated in blocking solution
(5% fat-free milk solution in PBS) for 2 h at room temperature.
Membranes were then washed three times in PBS-T (PBS, 0.05%
Tween 20), incubated with monoclonal antibodies directed
against human Cox-2 or Cox-1 (Alexis Biochemicals), washed
three times in PBS-T, and incubated with peroxidase-labeled
goat anti–mouse IgG (Pierce Chemical Co.). Membrane-bound
antibody was visualized with the Amersham Pharmacia Biotech
enhanced chemiluminescence (ECL) detection reagent.
 
Northern Blot and Nuclear Run-on Assays. 
 
For both assays,
confluent HUVECs were grown to confluence on 150-mm
dishes and maintained for 12 h in OPTI-MEM (Life Technolo-
gies), supplemented with 0.5% FCS, then pretreated with or
without CsA for 2 h and subsequently stimulated with VEGF for
the times indicated. For Northern blot analysis, total RNA was
isolated from treated and control HUVEC cultures using TRIzol
reagent (Life Technologies) as recommended by the manufac-
turer. A total of 20 
 
m
 
g was separated on formaldehyde gels and
blotted onto nylon membranes (Nytran; Schleicher & Schuell)
according to standard protocols (47). Human Cox-1, Cox-2, and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA
probes were labeled by the random priming method (47), and
hybridizations were performed overnight at 65
 
8
 
C in 7% SDS,
500 mM sodium phosphate buffer, pH 7.2, and 1 mM EDTA ac-
cording to Church and Gilbert (48). Filters were then washed
twice for 30 min each in 1% SDS and 40 mM sodium phosphate
buffer, pH 7.2, at 65
 
8
 
C, and blots were exposed to x-ray film for
autoradiography. Nuclear run-on reactions were performed es-
sentially as described previously (49). In brief, cells were dis-
rupted with NP-40 buffer (1% [vol/vol] NP-40, 50 mM Tris-
HCl, pH 7.5) and nuclei were collected by centrifugation.
Nuclear transcription assays were performed and [
 
32
 
P]UTP
(3,000 Ci/mmol; Amersham Pharmacia Biotech) labeled RNA
was isolated by the TRIzol reagent and then hybridized to nylon
membranes containing 5
 
 
 
m
 
g of dot-blotted linearized cDNAs for 
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Cox-2 and GAPDH, or Bluescript plasmid. Filters were hybrid-
ized with 2 
 
3
 
 
 
10
 
6
 
 cpm/ml, washed, and exposed as described
above.
 
Determination of Cyclooxygenase Activity. 
 
Confluent HUVECs
were maintained for 12 h in OPTI-MEM (Life Technologies),
supplemented with 0.5% FCS, then pretreated with or without
200 ng/ml CsA or 1 
 
m
 
M NS-398 for 2 h, and further stimulated
with VEGF for an additional 8 h in culture medium. Levels of the
stable metabolite of prostacyclin, 6-keto-PGF
 
1
 
a
 
, in the culture
supernatants, were determined using a commercial enzyme im-
munoassay (Amersham Pharmacia Biotech). To evaluate cycloox-
ygenase activity in intact cells, the media were aspirated after
treatment, the cells were rinsed twice with in HBS, pH 7.4, sup-
plemented with 0.1% BSA, and incubated for 30 min in the same
buffer plus 10 
 
m
 
M AA. The stable metabolite of prostacyclin,
6-keto-PGF
 
1
 
a
 
, was determined in the supernatants using the
same enzyme immunoassay described above. Results are ex-
pressed as picograms per 5
 
 3 
 
10
 
5
 
 cells, as direct counts showed no
major variation in cell number during the experiments. All sam-
ples were tested in triplicate.
 
Plasmid Constructs, Site-directed Mutagenesis, and Transient Trans-
fection Assays. 
 
Human Cox-2 promoter constructs were created
by cloning BamHI-BglII–flanked PCR products derived from
Jurkat genomic DNA into the BglII-digested pXP2Luc reporter
plasmid as described (50). For transient transfection experiments,
HUVECs were plated in 100-mm tissue culture dishes (1.5 
 
3
 
 10
 
6
 
cells/plate) the day before. Cells were transfected with 10 
 
m
 
g of
the indicated luciferase reporter plasmid in 4 ml DMEM plus 10%
FCS using a calcium phosphate procedure as described previously
(16). In brief, HUVECs were incubated with DNA for 4.5 h and
washed twice with PBS. Cells were then trypsinized, centrifuged,
resuspended in OPTI-MEM supplemented with 0.5% FCS, and
split among 24-well tissue culture plates (nine wells were from
one 100-mm dish) precoated with 0.5% gelatin. After 16 h, trans-
fected cells were exposed to different stimuli for 6 h. Luciferase
activity was measured according to the instructions of the Lu-
ciferase system kit (Promega). Transfection efficiency was nor-
malized by cotransfection with 0.1 
 
m
 
g of the Renilla luciferase
expression vector pRLCMV (Promega), measured by the Dual
luciferase assays kit (Promega). The results presented are ex-
pressed as the means and standard deviations of determinations
performed in triplicate. A representative experiment is shown of
the reporter assays in all cases.
In vitro–directed mutagenesis was performed with the Quick-
Change site-directed mutagenesis kit (Stratagene) as described
previously (50), with the following synthetic oligonucleotide
primers (lowercase letters indicate the mutated positions): GGG-
GAGAGGAGttAAcAATTTGTGGGGGGTACG (
 
2
 
115 to
 
2
 
83 dNFAT mutant primer); GGGGTACGAAAAGGCGtctA-
GAAACAGTCATTTCG (
 
2
 
89 to 
 
2
 
55 pNFAT mutant
primer); and GCCCCCACCGGCaTACcCAtTTTTTTTAA-
GGG (
 
2
 
144 to 
 
2
 
113 NFIL6 mutant primer). The nucleotide se-
quence of the mutants was confirmed by automatic DNA se-
quencing.
 
Electrophoretic Mobility Shift Assays. 
 
Nuclear extracts were
prepared from HUVECs as described previously (16). In brief, 2
 
m
 
g of nuclear protein was incubated with 1 
 
m
 
g of poly(dI-dC)
DNA carrier in DNA-binding buffer (10% [wt/vol] polyvinyl-
ethanol, 12.5% [vol/vol] glycerol, 50 mM Tris, pH 8, 2.5 mM
EDTA, 2.5 mM DTT) in a final volume of 10.5 
 
m
 
l on ice for 10
min. Then, 10
 
5
 
 cpm (10
 
8
 
 cpm/
 
m
 
g) of the 
 
32
 
P-labeled double-
stranded oligonucleotide (2 
 
m
 
l) were added, and the reaction was
incubated at room temperature for 30 min. For competition ex-
 
periments, a 20-fold molar excess of unlabeled oligonucleotide
was added before the addition of the probe. When indicated, nu-
clear extracts were incubated with 0.5 
 
m
 
l of either a preimmune
serum or the indicated antisera for 15 min at 4
 
8
 
C before the addi-
tion of the probe. DNA–protein complexes were resolved by
electrophoresis in 4% nondenaturing polyacrylamide gels.
The following synthetic oligonucleotides (5
 
9
 
 to 3
 
9
 
) were used
as probes/competitors in electrophoretic mobility shift assays
(EMSAs) were as follows (factor binding sites are underlined):
gatcGGAGGAAAAACTGTTTCATACAGAAGGCGT (distal
NFAT site of the human IL-2 promoter); tcgaCAAGGG-
GAGAGGAGGGAAAAATTTGTGGC (nucleotides 
 
2
 
117 to
 
2
 
91 containing the putative distal NFAT site of the human
Cox-2 promoter); tcgaCAAAAGGCGGAAAGAAACAGTCA-
TTTC (nucleotides 
 
2
 
82 to 
 
2
 
58 containing the putative proxi-
mal NFAT-AP1 site of the human Cox-2 promoter); gat-
cAGTGGGGACTACCCCCT (nucleotides 
 
2
 
277 to 211 con-
taining the NF-
 
k
 
B site of the human Cox-2 promoter); and
gatcGGCTTACGCAATTTTT (
 
2
 
135 to 
 
2
 
123 containing the
NF-IL6 site of the human Cox-2 promoter).
 
In Vitro Angiogenesis Assay. 
 
HUVECs were trypsinized,
counted, and resuspended (2.0 
 
3
 
 10
 
4
 
 cells/well) in OPTI-MEM
supplemented with 1% FCS. Cells were treated with 200 ng/ml
CsA, 50 ng/ml VEGF, 10 
 
m
 
M NS-398, neutralizing goat anti-
bodies against VEGF and bFGF (rhVEGF
 
165
 
, rhVEGF
 
121
 
, and re-
combinant human bFGF from R&D Systems), or vehicle as indi-
cated. Matrigel basement membrane matrix (Becton Dickinson)
was diluted 1:2 in cold serum-free RPMI 1640, without growth
factors and heparin. 50 
 
m
 
l diluted Matrigel was plated into flat-
bottomed 96-well tissue culture plates and allowed to gel for 1–2 h
at 37
 
8
 
C, before cell seeding. Then, the cell suspension was plated
(80
 
 m
 
l/well) onto the surface of the Matrigel and incubated at
37
 
8
 
C. After 12 h, cells were photographed using a ZEISS in-
verted phase–contrast photomicroscope. Capillary tubes were de-
fined as cellular extensions linking cell masses or branch points,
and tube formation was quantified from photographs of standard-
ized fields from triplicate wells.
 
Corneal Neovascularization Assay. 
 
The assay was performed as
described previously (48). In brief, hydron-sucralfate pellets of
 
z
 
1 
 
m
 
l containing 50 ng/pellet bFGF or 100 ng/pellet VEGF
alone or in combination with a 20 
 
m
 
g/ml anti–TGF-
 
b
 
 antibody
were implanted into a pocket surgically created in avascular cor-
neas of anesthetized C57/Bl6 mice (National Cancer Institute,
Bethesda, MD) 0.5–1 mm from the limbus. CsA (20 mg/kg/d),
PGE
 
2
 
 (0.1 mg/kg/d), and NS-398 (5 mg/kg/d) were adminis-
tered by intraperitoneal injections. Neovascularization was ob-
served on day 5 after implantation. Vigorous ingrowth of the
blood vessels in the direction of the pellet was scored as a positive
response.
 
Collagen Gel Assays.
 
HUVECs were trypsinized, counted,
and resuspended (10
 
5
 
 cells/well) in serum-free endothelial basal
growth medium (EBM; Life Technologies). Cells were pretreated
with 200 ng/ml CsA for 2 h and further stimulated with 50 ng/
ml VEGF, 10 ng/ml bFGF, or 1 ng/ml PGE
 
2
 
. Three-dimen-
sional collagen gels were prepared by diluting type I collagen
(ICN Biomedicals) in serum-free DMEM (GIBCO BRL) at a fi-
nal concentration of 500 
 
m
 
g/ml. 500 
 
m
 
l diluted collagen was
placed into flat-bottomed 24-well tissue culture plates and al-
lowed to gel for 1–2 h at 37
 
8
 
C, before cell seeding. Cell suspen-
sions were plated (500
 
 m
 
l/well) onto the surface of the gels and
incubated at 37
 
8
 
C. The gels were photographed under a phase–
contrast microscope and migrating cells (dendritic-shaped cells,
whose plane of focus was beneath the surface monolayer) were 
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counted in four random fields per well (original magnifications:
 
3
 
20). All experiments were performed in triplicate.
 
Cell Migration Assays. 
 
Migration assays were performed us-
ing dermal microvascular endothelial cells as described previously
(51). Cells were incubated overnight in EBM containing 0.1%
BSA, collected, resuspended in EBM plus 0.1% BSA, at 1.0–
1.5
 
 3 
 
10
 
6
 
 cells/ml containing CsA where indicated and plated on
the lower surface of gelatinized 5.0-
 
m
 
m pore filter (Nucleopore)
in an inverted, modified Boyden chamber. Cells were allowed to
adhere for 2 h at 37
 
8
 
C, the chambers were reinverted, test sam-
ples were added to the top well, and the chamber was incubated
at 37
 
8
 
C to allow migration. Chambers were then disassembled,
membranes were fixed and stained, and the number of cells that
had migrated to the top of the filter in 10 high power fields were
counted (1 high power field 
 
3
 
1,000). EBM supplemented with
0.1% BSA was used as a negative control to measure background
resulting from random migration. All samples were tested in qua-
druplicate.
 
Results
VEGF Induces Cox-2 Gene Expression in HUVECs. It
has been reported that Cox-2 regulates angiogenesis by
modulating the production of angiogenic factors (27), and
that Cox-2 inhibitors prevent in vitro angiogenesis induced
by VEGF and bFGF (29). To test whether VEGF regulates
Cox-2 expression in endothelial cells, we carried out West-
ern blot experiments in HUVEC extracts obtained at dif-
ferent times after treatment with VEGF. These experi-
ments showed that Cox-2 protein, expressed at very low
levels in unstimulated cells, was already induced 4 h after
VEGF treatment, reached higher levels of expression at
8–12 h, and markedly declined to baseline levels by 24 h
(Fig. 1 A). By contrast, Western blot analysis experiments
showed that the levels of Cox-1 remained unchanged after
the treatment with VEGF (Fig. 1 B).
We have shown previously that in HUVECs, VEGF ac-
tivates the calcium/calcineurin signaling pathway and the
translocation of NFAT to the nucleus, leading to the induc-
tion of expression of tissue factor in a CsA-sensitive fashion
(16). In addition, Cox-2 gene expression has been shown
to be induced early during T cell activation, a process that is
also dependent on NFAT and inhibited by CsA (18, 31,
50). Therefore, we analyzed the potential involvement of
this pathway in the regulation of Cox-2 gene expression in
HUVECs. As shown in Fig. 1 A, pretreatment of cells with
CsA completely abrogated the induction of Cox-2 by
VEGF. This inhibitory effect was dose dependent and oc-
curred at the same concentration range that was inhibitory
for NFAT in T lymphocytes or HUVECs (16, 17, 24, 52).
Thus, concentrations of CsA in the range of 50–200 ng/ml
efficiently inhibited the induction of Cox-2 by VEGF in
HUVECs and by PMA plus calcium ionophore in Jurkat T
cells (data not shown). Exposure of HUVECs to TNF-a
also resulted in Cox-2 protein induction. However, this in-
duction was refractory to inhibition by CsA, and displayed
a different kinetic of expression to that induced by VEGF.
As shown in Fig. 1 C, Cox-2 induction by TNF-a oc-
curred 8 h later and protein levels remained high even 24 h
after treatment. Another angiogenic growth factor, bFGF,
induced early onset of CsA-resistant expression of Cox-2 in
HUVECs. This induction, more transient than that in-
duced by VEGF or TNF-a, was observed by 4–8 h and de-
creased to basal levels 12 h after stimulation (Fig. 1 D).
To determine the level at which VEGF regulates the ex-
pression of Cox-2 protein, we initially performed North-
ern blot analysis using RNA isolated from HUVECs acti-
vated with VEGF in the presence or absence of CsA. In
these experiments, very low levels of Cox-2 mRNA found
in unstimulated cells were clearly upregulated by VEGF in
a CsA-sensitive manner (Fig. 2 A). In accordance with the
results obtained by Western blotting, constitutive expres-
sions of Cox-1 and GAPDH mRNAs were not modified
by VEGF or CsA (Fig. 2 A). Nuclear run-on studies
showed that transcription of Cox-2 gene, undetectable in
Figure 1. VEGF induces Cox-2 in
HUVECs in a CsA-sensitive manner.
HUVECs, either pretreated with or
without CsA (200 ng/ml) for 2 h were
left untreated (2) or were treated with
50 ng/ml VEGF (A and B), 50 ng/ml
TNF-a (C), or 10 ng/ml bFGF (D), for
the indicated periods of time. Cell ex-
tracts were analyzed by Western blot
probed with anti–Cox-2, anti–Cox-1,
or anti–b-tubulin antibodies to ensure
equal loading. The data are representa-
tive of at least three independent experi-
ments with similar results.611 Hernández et al.
and to evaluate the potential contribution of the NFAT
sites, we conducted transfection experiments in HUVECs
with luciferase reporter plasmids driven by a series of dele-
tion fragments spanning from positions 21796 bp down to
246 bp upstream of the Cox-2 gene transcription start site.
We analyzed the transcriptional inducibility of these con-
structs by VEGF. These experiments showed that tran-
scription driven by constructs with deletions spanning from
21796 to 288 of the Cox-2 promoter region (P2-1900 to
P2-192 deletion constructs) was efficiently induced by
VEGF, but that the 288 to 246 bp promoter region con-
tained sequences essential for VEGF-dependent induction
of the Cox-2 promoter (Fig. 4). In accordance with West-
ern blot and reverse transcription PCR experiments, CsA
inhibited the activation of all reporter constructs by VEGF
(Fig. 4). Therefore, cis-acting elements mapping between
the nucleotides at positions 288 to 246 appear to be re-
quired for the VEGF-mediated activation of the Cox-2
promoter. In addition, the CsA-sensitive inducibility of
Cox-2 expression strongly suggested the implication of the
Ca21/calcineurin pathway in the VEGF-mediated induc-
tion of the Cox-2 gene.
VEGF Induces NFAT-binding Activity to the Cox-2 Pro-
moter. Two motifs including the NFAT core and an AP-
1–like site were located within the 246 to 2170 bp region
of the Cox-2 promoter. Because of the critical role of this
region for the inducibility of the promoter by VEGF, we
Figure 2. Effect of VEGF on Cox-2 transcription. HUVECs
were pretreated with or without 200 ng/ml CsA for 2 h and further
stimulated with 50 ng/ml VEGF for the time points indicated, and
total or nuclear RNA was analyzed by Northern blot or nuclear
run-on, respectively. (A) Northern blot analysis from HUVECs ac-
tivated by VEGF. After isolation, 20 mg RNA was separated by
agarose gel electrophoresis, blotted onto a nitrocellulose membrane,
and hybridized with a human Cox-2 cDNA probe, then sequen-
tially rehybridized with Cox-1 and GAPDH-specific cDNA
probes. (B) Nuclear run-on analysis using nuclear RNA from HUVECs activated by VEGF. Nuclear RNA samples, labeled with [32P]UTP, were hybrid-
ized to nylon membrane containing 5 mg of dot-blotted linearized cDNAs for Cox-2, GAPDH, or Bluescript plasmid. The results shown in the autoradio-
graphs (top) are represented (in arbitrary densitometric units of Cox-2/GAPDH) as fold induction over the baseline levels of unstimulated cells (1) (bottom).
control untreated HUVECs, was significantly increased by
0.5–2 h of treatment with VEGF. Furthermore, this
VEGF-driven stimulation of the Cox-2 transcription rate
was also sensitive to CsA (Fig. 2 B). As expected, the in-
duction of expression of Cox-2 by VEGF resulted in the
upregulation of cyclooxygenase activity, as was evidenced
by the increased production of prostacyclin, determined as
6-keto-PGF1a accumulation in the supernatants of VEGF-
treated endothelial cells (Fig. 3 A). Moreover, VEGF also
induced an increase in prostacyclin synthesis in a direct as-
say of Cox activity in intact cells in the presence of AA
(Fig. 3 B). In each case, the stimulation of prostacyclin by
VEGF was sensitive to the specific Cox-2 inhibitor NS-
398 and was efficiently inhibited by CsA (Fig. 3, A and B).
Transcriptional Regulation of the Cox-2 Promoter by VEGF
and TNF-a. The 59 flanking region of the Cox-2 gene
contains an E box, a CRE, and functional binding sites for
NF-IL6 (C/EBP-b) and NF-kB. In addition, we have re-
cently identified two NFAT sites involved in the regulation
of Cox-2 gene expression during T cell activation (50).
These sites contain the GGAAA NFAT core sequence and
are located at positions 271 and 2101 relative to the tran-
scription start site of the gene. They are designated as prox-
imal and distal NFAT (pNFAT and dNFAT) sites, respec-
tively (Fig. 4, top).
To analyze whether the VEGF-mediated upregulation of
Cox-2 expression could be reflected at the promoter level,612 NFAT-regulated Cox-2 Gene Expression in Angiogenesis
analyzed the ability of these sites to bind NFAT. For this
purpose, we designed synthetic oligonucleotides that in-
cluded the pNFAT and dNFAT sites, and used them as
probes in EMSAs. Both the dNFAT and the pNFAT Cox-2
probes efficiently and specifically bound to nuclear proteins
from VEGF-treated HUVECs. This was evidenced by
competition of the major retarded band with a 20-fold mo-
lar excess of an unlabeled NFAT consensus probe. Further-
more, CsA blocked the formation of the specific complexes
generated with both probes (Fig. 5, A and B). The involve-
ment of NFAT in this binding was further confirmed using
an anti–all-NFAT antiserum directed against a common
epitope of the DNA-binding domain of all NFAT mem-
bers, which completely abolished the formation of the spe-
cific complexes (Fig. 5, A and B). In agreement with our
previous work (16), TNF-a was unable to induce specific
binding to both NFAT probes. Similarly, VEGF failed to
induce binding to the NF-kB or NF-IL6 sites of the Cox-2
promoter (data not shown). These results indicate that
VEGF induced binding to the NFAT motifs within the
Cox-2 gene promoter in a CsA-sensitive manner.
Essential Role of NFAT for the Transcriptional Regulation of
Cox-2 by VEGF. Given the relevance of the region span-
ning from nucleotides 288 to 246 for the inducibility of
the Cox-2 promoter by VEGF, as well as the presence of
functional NFAT binding sites within this region (Figs. 4
and 5), we next determined the contribution of these sites
to the overall transcriptional regulation of the Cox-2 pro-
moter by VEGF. To this end, we performed site-directed
mutagenesis experiments using the parental P2-274 (2170,
1104) wild-type construct as a template to generate spe-
cific mutations within the dNFAT site, the pNFAT site, or
both. We also introduced a 3-bp substitution into the core
region of the NF-IL6 site of the P2-431 (2327, 1104)
construct for comparison (Fig. 6 A). Transfection experi-
ments with these plasmids indicated that mutation of the
dNFAT site resulted in a 20–30% loss in the VEGF-
Figure 3. Induction of prostacyclin synthesis by VEGF. HUVECs
were pretreated or not with 200 ng/ml CsA or 1 mM NS-398 for 2 h and
subsequently treated with VEGF (50 ng/ml) for an additional 8-h period,
and the levels of 6-keto-PGF1a were determined in the culture medium
supernatants (A) or in the supernatants of intact cells after addition of 10
mM AA (B). Prostacyclin (determined as 6-keto-PGF1a) was quantified
by using an enzyme immunoassay. Two independent experiments yield-
ing similar results were performed in triplicate. Results are expressed as
picogram per 5 3 105 cells.
Figure 4. Activation of Cox-2
gene promoter by VEGF. HUVECs
were transfected with the different
Cox-2 promoter reporter plasmids
for 4.5 h. 16 h later, the cells were
pretreated with 200 ng/ml CsA for
2 h where indicated, and stimulated
with 50 ng/ml VEGF for an addi-
tional 6 h. Experiments were per-
formed in triplicate. Luciferase activ-
ity is expressed as fold induction
over the baseline levels of transfected
unstimulated cells. Results of a rep-
resentative experiment out of three
performed are shown. Deletions
ranging from 21796 to 246 relative
to the transcription start site of the
Cox-2 promoter were used. The ex-
tent of the 59 truncations is shown
with numbers indicating positions
relative to the transcription start site.
Consensus sequences are denoted by
boxes.613 Hernández et al.
induced reporter activity, whereas mutation of pNFAT
alone, or double mutation of the dNFAT and pNFAT (P2-
274 d&pNFAT mut construct) caused .90% reduction in
the inducibility of the promoter by VEGF (Fig. 6 B). By
contrast, the mutation of the NF-IL6 site hardly affected
the inducibility of the promoter by VEGF (Fig. 6 B).
Therefore, the pNFAT site is required for the inducibility
of the Cox-2 promoter by VEGF.
In Vitro Inhibition of Endothelial Cell Migration and Angio-
genesis by CsA. Recently, NSAIDs have been shown to
inhibit angiogenesis through direct effects on endothelial
cells (29). In view of our findings that VEGF induces Cox-2
gene expression, as well as the requirement of NFAT and
the sensitivity to CsA of this process, we proceeded to test
whether CsA was an inhibitor of VEGF-induced angio-
genesis. We evaluated the effect of CsA on the ability of
HUVECs to form capillary-like structures when seeded on
Matrigel. We initially found that CsA alone significantly
inhibited tube formation of HUVECs in Matrigel (Fig. 7
A). VEGF, and also PGE2, induced a significant increase in
the number of capillary-like structures compared with that
observed with Matrigel alone. The specific contribution of
endogenously secreted VEGF to the overall in vitro angio-
genesis was assessed by adding saturating amounts of an
anti-VEGF neutralizing antibody to the Matrigel. It is
noteworthy that the inhibition displayed by the anti-VEGF
antibody was very similar to that obtained with CsA (Fig. 7
A). Furthermore, the inhibition displayed by CsA was as
potent as that exerted by the selective Cox-2 inhibitor NS-
398 (Fig. 7 A). Since CsA has been shown to induce TGF-b
in other experimental models (53), we also analyzed the
Figure 5. VEGF induces NFAT–DNA binding activity to the Cox-2
promoter. Nuclear extracts from HUVECs stimulated for 20 min with 50
ng/ml VEGF with or without 200 ng/ml CsA were analyzed by EMSA
with probes including the distal NFAT site of the Cox-2 human promoter
(nucleotides 2117 to 291) (A) or the proximal NFAT site of the Cox-2
human promoter (nucleotides 282 to 258) (B). A 20-fold molar excess of
the unlabeled NFAT consensus site oligonucleotide of the IL-2 promoter
was added to the binding reaction mixtures to determine the specificity of
the binding. EMSAs were performed in the presence or absence of either
preimmune serum (Preimm.) or the 674 anti–all-NFAT (a-all) antiserum.
The specific DNA–NFAT complexes are indicated by an arrow.
Figure 6. Role of NFAT for the
Cox-2 promoter activity induced by
VEGF. (A) Sequences of the wild-
type and mutated NFAT and NF-
IL6 sites of the Cox-2 gene pro-
moter. The consensus sequences are
marked in bold and the substitutions
introduced are indicated by dots. (B)
Reporter vectors harboring muta-
tions in the NFAT or NF-IL6 sites
were transfected into HUVECs for
4.5 h. 16 h after transfection, the
cells were stimulated with 50 ng/ml
VEGF for 6 h and luciferase activity
was determined. The activity is ex-
pressed as fold induction over the
baseline levels of transfected unstim-
ulated cells. One out of three inde-
pendent experiments performed is
shown. The P2-274 (2170, 1104)
and P2-431 (2327,  1104) con-
structs were used as templates for
site-directed mutagenesis. Mutated
sites are indicated by X.614 NFAT-regulated Cox-2 Gene Expression in Angiogenesis
effect of a neutralizing anti–TGF-b antibody on tube for-
mation in Matrigel. However, anti–TGF-b did not inter-
fere with the inhibitory effect of CsA or with the proangio-
genic properties of exogenous VEGF. Because bFGF,
which induced Cox-2 gene expression in a CsA-insensitive
fashion (Fig. 1 D), was present in Matrigel, we also tested
the ability of CsA and NS-398 to interfere with tube for-
mation in the presence of exogenous recombinant VEGF
(Fig. 7 B). Under these conditions both CsA and NS-398
inhibited tube formation, and this effect was completely
abolished by the addition of exogenous PGE2 (Fig. 7, A
and B). Conversely, the addition of exogenous bFGF
caused an increase in the basal levels of tube formation in
Matrigel that was not affected by CsA (Fig. 7 D).
To identify possible specific functions of endothelial cells
that could be targeted by CsA, we next analyzed the effect
of 200 ng/ml CsA on VEGF-induced incorporation of
[3H]thymidine and proliferation of HUVECs. However,
CsA failed to interfere with these processes. At higher doses
of CsA, we observed inhibition of VEGF- and fetal bovine
serum–induced proliferation (data not shown). Since 200
ng/ml of CsA completely blocks the VEGF-mediated acti-
vation of NFAT and Cox-2 expression in HUVECs, these
effects of high doses of CsA did not appear to be mediated
Figure 7. Inhibition of in vitro endothelial cell morphogenesis by CsA. HUVECs (2 3 104 cells/well) were seeded into 96-well plates precoated with
50 ml of Matrigel. HUVECs were untreated (control) or treated with CsA, a neutralizing anti-VEGF antibody, NS-398, PGE2, a neutralizing anti–TGF-b
antibody alone (A), or in the presence of exogenous VEGF (B). (C) Representative photographs (original magnifications: 3100) of five different fields
corresponding to the experiments showed in A and B. (D) HUVECs either pretreated with or without CsA were treated with VEGF or bFGF and tube
formation was quantified. Results are expressed as the percentage of tubes formed in the presence of CsA relative to the tubes formed in the presence of
VEGF (100%) or bFGF (100%). For the different treatments shown in A, B, and C, 200 ng/ml CsA, 50 ng/ml VEGF, 10 ng/ml bFGF, 1 ng/ml PGE2,
10 mg/ml of anti-VEGF antibody, 4 mg/ml of anti–TGF-b antibody, and 10 mM NS-398 were used alone or in the indicated combinations. When used,
CsA was added 1 h before the cells were plated on Matrigel, and then its concentration was maintained during the treatment. Tube formation was quan-
tified 12 h after cells were plated in Matrigel by counting the number of tubular structures in four to six fields. Results are representative of at least four
independent experiments performed.615 Hernández et al.
by NFAT or Cox-2. Likewise, we did not detect any sig-
nificant effect of CsA on the levels of KDR/Flk-1 VEGF
receptor in HUVECs exposed to VEGF (data not shown).
However, the migration of HUVECs into a type I collagen
gel in response to VEGF was severely impaired by CsA
(Fig. 8 A). In a Boyden chamber assay, primary microvas-
cular endothelial cells were unable to migrate up the gradi-
ent of VEGF in the presence of CsA (Fig. 8 B), while the
bFGF-induced migration was unaffected by CsA in each
type of migration assays (Fig. 8, A and B).
In Vivo Inhibition of Angiogenesis by CsA. To determine
whether the inhibitory effect of CsA on in vitro angiogene-
sis of HUVECs was also operative in vivo, we examined
the effect of CsA on corneal angiogenesis. For this purpose,
we implanted pellets containing VEGF or bFGF in corneas
of mice systemically treated with 20 mg/kg CsA once every
2 d or vehicle alone. As shown in Table I, after 5 d of pellet
implantation both bFGF and VEGF effectively induced
vigorous neovascularization in 4/4 and 11/12 corneas, re-
spectively. However, CsA-treated mice yielded a differen-
tial response depending on the angiogenic stimulus used.
Thus, while in mice implanted with pellets containing
bFGF the systemic treatment with CsA had no effect on
corneal neovascularization, CsA markedly inhibited that
mediated by VEGF (Fig. 9 A and Table I). In these experi-
ments 100% of mice receiving bFGF implants displayed a
Figure 8. Effect of CsA on endothelial cell migration.
(A) Phase–contrast micrographs of migrating cells invading
collagen gels and forming tubelike structures. HUVECs
were seeded onto the surface of collagen gels, in the pres-
ence or absence of 50 ng/ml VEGF or 10 ng/ml bFGF,
and were tested alone or in combination with 200 ng/ml
CsA for 24 h (top). Migrating cells were quantified under
the different conditions with respect to control cells in the
presence of VEGF (100%) or bFGF (100%) (bottom). (B)
Migration of dermal microvascular endothelial cells. 200
ng/ml CsA was tested for its ability to inhibit endothelial
cell migration induced by 100 pg/ml VEGF or 20 ng/ml
bFGF. Endothelial cells in EBM plus 0.1% BSA were
plated onto the lower surface of a gelatinized 5.0-mm filter
in an inverted, modified Boyden chamber. Results are ex-
pressed as the number of cells migrated by 10 high power
fields. EBM supplemented with 0.1% BSA was used as a
negative control (background resulting from random mi-
gration). One representative experiment out of three inde-
pendent performed is shown.616 NFAT-regulated Cox-2 Gene Expression in Angiogenesis
positive angiogenic response regardless of the treatment
with CsA, whereas in response to VEGF only 2/10 corneas
displayed a significant ingrowth of vessels (Table I). The
presence of an anti–TGF-b neutralizing antibody did not
interfere with the inhibitory effects of CsA on corneal an-
giogenesis, and similar results were obtained with VEGF
and bFGF in the presence or absence of anti–TGF-b anti-
body (Fig. 9 A and Table I). As in the case of migration and
Matrigel assays, the inhibition of the VEGF-mediated cor-
neal angiogenesis by CsA was significantly restored by the
systemic treatment of mice with PGE2 (Fig. 9 B and Table
II). Furthermore, as also observed in the Matrigel assays, the
effect of NS-398 on corneal neovascularization was similar
to that of CsA. In this set of experiments, while 100% cor-
neas displayed a positive angiogenic response to VEGF,
only 1/8 corneas (12.5%) from mice receiving systemic
treatment with NS-398 or CsA displayed a significant capil-
lary ingrowth in response to VEGF (Fig. 9 B and Table II).
Discussion
VEGF is a potent mitogen for endothelial cells involved
in physiological and pathological angiogenesis. VEGF
switches on a multistep program that leads to the activa-
tion, proliferation, migration, and differentiation of endo-
thelial cells. Because of the complexity of this program, a
high number of genes are expected to be involved in the
regulation of these processes, but a rather limited number
of VEGF-induced genes has been described so far. In this
study, we have identified Cox-2 as one of the genes in-
duced by VEGF, and characterized the molecular mecha-
nisms involved in the regulation of this gene by VEGF in
HUVECs. We have shown that activation of Cox-2 gene
expression by VEGF requires the activation of the calcium/
calcineurin-regulated NFAT transcription factor, and that
both the VEGF-mediated angiogenesis and the induction
of Cox-2 gene expression are CsA-sensitive processes.
Table I. Inhibition of Corneal Neovascularization by CsA
 No  antibody Anti–TGF-b
Sample PBS bFGF VEGF PBS bFGF VEGF
Olive oil  0/4 4/4* 11/12* 1/4 5/5 7/8
CsA 0/3 4/4 2/10* 0/4 6/6 2/8*
VEGF (100 ng/pellet) or bFGF (50 ng/pellet), alone or in combination
with anti–TGF-b (20 mg/ml), were incorporated into hydron-sucralfate
slow-release pellets that were inplanted into the avascular corneas of
both eyes in C57/Bl6 mice. The animals were injected with CsA (20
mg/kg once every 2 d) or control vehicle (olive oil, 10% ethanol).
Vigorous ingrowth of new capillaries from the limbus towards the
pellets was cored as a positive response. Maximum response was
observed on day 5 after implantation. Ratios indicate the number of
positive corneas/total implanted. Photographs of the representative
corneas are shown in Fig. 9 A.
*One cornea gave a mild response with a few sprouting vessels that did
not reach the pellet.
Figure 9. Inhibition of corneal neovascularization by
CsA and NS-398. VEGF or bFGF, alone or in combina-
tion with anti–TGF-b, were incorporated into pellets and
implanted in corneas of mice that were treated systemically
with CsA or control vehicle (A), with CsA in combination
with PGE2, or with NS-398 alone (B) as indicated in Ta-
bles I and II. Vigorous ingrowth of new capillaries from
the limbus towards the pellets was scored as a positive re-
sponse. Maximal response was observed at day 5 after im-
plantation. (A) Photographs of representative corneas from
the experiment summarized in Table I. (B) Representative
corneas from the experiment summarized in Table II.617 Hernández et al.
We have found that Cox-2 is differentially regulated by
TNF-a and VEGF in HUVECs. Previous studies have re-
vealed the functional roles of NF-kB, NF-IL6, ATF/
CRE, and E box motifs in Cox-2 promoter regulation de-
pending on the cell type and the stimuli used. In HU-
VECs, TNF-a but not VEGF required NF-IL6 for the
transcriptional activation of Cox-2 promoter (Hernandez,
G.L., and J.M. Redondo, unpublished data). On the other
hand, VEGF efficiently induces NFAT binding activity to
two functional (pNFAT and dNFAT) sites within the
Cox-2 gene promoter, one of which was essential for the
transcriptional response to VEGF. By contrast, the double
mutation of NFAT sites or the treatment with CsA failed
to affect the promoter inducibility by TNF-a (data not
shown). Consistent with this, reverse transcription PCR
experiments indicated that TNF-a upregulated the expres-
sion of Cox-2 mRNA, but CsA failed to inhibit this in-
duction (data not shown).
We have recently reported the relevance of these NFAT
sites in the regulation of the Cox-2 promoter upon T cell
activation (50), a process where the activation of the Ca21/
calcineurin pathway is essential for the activation of several
important genes (18, 24). Since NFAT activation is blocked
by CsA, the requirement for this transcription factor in the
VEGF-mediated expression of the Cox-2 is consistent with
the efficient inhibition exerted by CsA on the activation of
Cox-2 gene promoter, transcription, protein expression,
and prostacyclin synthesis induced by VEGF. Using differ-
ent experimental approaches, we have clearly shown a se-
lective upregulation of Cox-2 gene expression and activity
by VEGF. These results are in disagreement with the previ-
ous work by Bryant et al., where VEGF was found to in-
duce Cox-1 but not Cox-2 in endothelial cells (54). The
reasons for these discrepancies are at present unknown.
Several epidemiological and clinical studies have docu-
mented reduction of cancer risk in patients treated with
NSAIDs (55–57). Because of the ability of these drugs to
inhibit cyclooxygenase enzymes, a number of studies have
been focused on the role of these enzymes in cancer. Thus,
a markedly increased expression of Cox-2, but not Cox-1,
was found in .80% of colon adenocarcinomas (58). In an-
imal models of colorectal neoplasia both the increased lev-
els of Cox-2 in tumors and the beneficial effects of Cox in-
hibitors in preventing polyp formation and carcinogenesis
were found (for a review, see reference 57). Cox-2–defi-
cient mice are also protected in a genetic model of intesti-
nal polyposis (59). Besides the involvement of Cox-2 in
colorectal neoplasia, recent studies have also provided evi-
dence for a role for cyclooxygenase enzymes regulating an-
giogenesis (27–29), thus establishing a potential new mech-
anism linking Cox-2 induction and tumor progression. In
vitro angiogenesis experiments using cocultures of endo-
thelial cells and colon carcinoma cells showed the ability of
NSAIDs to downregulate the production of proangiogenic
factors by colon carcinoma cells, leading to the inhibition
of angiogenesis (27). More recently, NSAIDs have been re-
ported to inhibit endothelial tube formation through a di-
rect effect on endothelial cells (29). In view of the ability of
VEGF to induce Cox-2 in HUVECs that we reported
here, the inhibition of angiogenesis by NSAIDs would ap-
pear to be mediated not only by their effect on the produc-
tion of VEGF and other angiogenic factors (27), but also
through interference with the VEGF-mediated activation
of Cox-2 in endothelial cells. Similarly, the direct inhibi-
tion displayed by Cox-2 inhibitors on angiogenesis of en-
dothelial cells in Matrigel (29) may be explained, at least in
part, by our results identifying the Cox-2 gene as a target
induced by VEGF in endothelial cells.
CsA is an immunosuppressive drug whose effects on the
immune system appear to be mediated through the inhibi-
tion of NFAT (18, 24). Our results indicate that CsA can
also inhibit angiogenesis induced by VEGF in vivo and in
vitro. The inhibitory effect of CsA on angiogenesis in
Matrigel assay becomes discernible at doses similar to those
required to inhibit lymphocyte activation, is coincidental
with the inhibition of Cox-2 expression, and is consistent
with the requirement of NFAT for the expression of this
gene. Furthermore, the extent of inhibition of capillary
morphogenesis by CsA was similar to that displayed by
both NS-398, a selective inhibitor of Cox-2, and a neutral-
izing anti-VEGF antibody. In addition, the inhibition by
CsA of endothelial migration and in vivo and in vitro an-
giogenesis was reversed by PGE2, further eliminating possi-
ble nonspecific toxic effects of this drug. Taken together,
our data strongly suggest an important role for NFAT in
VEGF-induced angiogenesis that would be mediated, and
least in part, through the regulation of Cox-2 gene expres-
sion. However, our data do not demonstrate a direct in-
volvement of NFAT in angiogenesis. Given the functional
redundancy displayed by different NFAT family members,
as well as the embryonic lethality seen in NFATc null mice
(60, 61), an approach based on the analysis of angiogenesis
in NFAT deficient mice presents considerable difficulties.
In this regard, other alternative approaches such as the
study of angiogenesis in transgenic mice expressing either
Table II. Effects of NS-398 and PGE2 on Corneal Neovascularization
VEGF Systemic treatment Positive corneas/total implanted
1 Olive oil 6/6
1 CsA 1/8*
1 CsA 1 PGE2 5/8‡
1 NS-398 1/8§
2 Olive oil 0/4
2 CsA 0/3
Animals were injected with CsA (20 mg/kg once every 2 d) alone or in
combination with PGE2 (0.1 mg/kg/d) or with NS-398 (5 mg/kg/d)
alone, and the corneal response to VEGF (100 ng/pellet) was analyzed.
“Weak response” describes corneas in which a few sprouting vessels
were observed that did not reach the pellet. Photographs of the
representative corneas are shown in Fig. 9 B.
*One weak positive response.
‡Two weak positive responses.
§Three weak positive responses.618 NFAT-regulated Cox-2 Gene Expression in Angiogenesis
dominant negative versions of NFAT or inhibitory cal-
cineurin binding peptides (62) in a conditional fashion, will
be very useful in addressing the actual role of NFATs in an-
giogenesis in the adult. Despite all these considerations, and
taking into account the major role VEGF plays in physio-
logical and pathological angiogenesis, our results also sug-
gest that CsA could be used for antiangiogenic purposes. In
fact, CsA has been shown previously to retard neovascular-
ization in the cornea in a rat xenotransplantation model
(63), and to inhibit matrix metalloprotease-2 secretion,
chemotaxis, proliferation, and morphogenesis in a trans-
formed endothelial cell line in vitro (64). However, a dose-
dependent inhibitory effect of CsA reported by Iurlaro et
al. (64) was observed at concentrations 10–80-fold higher
than those required for either the NFAT inhibition, or the
blockade of in vitro angiogenesis in HUVECs. In this re-
gard, we have also found that although CsA at doses of 200
ng/ml (or lower) failed to interfere with the proliferation of
HUVECs, at higher doses it inhibited proliferation of HU-
VECs. However, we have previously shown that doses of
200 ng/ml completely block the translocation, DNA bind-
ing, and transactivation of NFAT in HUVECs (16), and
we have shown in the current study that the same doses
block the VEGF-mediated expression of the Cox-2 gene.
Thus, it appears that the inhibitory effects observed at
higher doses of CsA are not mediated through NFAT inhi-
bition or related to the inhibition of Cox-2. In fact, we
have compared the ability of different doses of CsA to in-
hibit Cox-2 activation in HUVECs and T lymphocytes ac-
tivated with PMA plus Ca21 ionophore. These experi-
ments revealed that the doses of CsA (50–200 ng/ml)
previously shown to inhibit cell activation and NFAT in T
lymphocytes (24, 52) were similarly effective at inhibiting
Cox-2 expression in HUVECs (data not shown). These re-
sults also suggest that calcineurin levels in HUVECs and T
lymphocytes are similar.
CsA has been reported to induce the synthesis of TGF-b
(53). However, we have found that neutralizing anti–TGF-b
antibodies had an effect on neither the CsA-mediated inhi-
bition of in vitro angiogenesis nor in vivo corneal neovas-
cularization induced by VEGF. Thus, despite the potential
side effects of CsA via its ability to induce TGF-b, CsA
clearly displays antiangiogenic activity. This property of
CsA may mediate some of the beneficial effects of the drug
observed in nonneoplastic pathologies such as rheumatoid
arthritis and psoriasis, where angiogenesis is associated with
an enhanced expression of VEGF and its receptors (65, 66).
In addition, non–immune-mediated situations in which
VEGF-mediated neovascularization occurs, such as diabetic
retinopathy (67, 68), could also be potential therapeutic
targets of CsA. Our results encourage studies to evaluate
the therapeutic potential of this drug in animal models of
retinopathy that, if successful, could easily be expanded to
clinical trials.
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